


XIENCE™ STENT: MOST STUDIED,  
MOST IMPLANTED STENT IN THE WORLD



ORDERING INFORMATION

STENT DIAMETER	LENGTH								POST-DILATATION LIMIT
	8 mm	12 mm	15 mm	18 mm	23 mm	28 mm	33 mm	38 mm	
2.0 mm	1508200-08	1508200-12	1508200-15	1508200-18	1508200-23	1508200-28	1508200-33	1508200-38	3.75 mm
2.25 mm	1508225-08	1508225-12	1508225-15	1508225-18	1508225-23	1508225-28	1508225-33	1508225-38	3.75 mm
2.5 mm	1508250-08	1508250-12	1508250-15	1508250-18	1508250-23	1508250-28	1508250-33	1508250-38	3.75 mm
2.75 mm	1508275-08	1508275-12	1508275-15	1508275-18	1508275-23	1508275-28	1508275-33	1508275-38	3.75 mm
3.0 mm	1508300-08	1508300-12	1508300-15	1508300-18	1508300-23	1508300-28	1508300-33	1508300-38	3.75 mm
3.25 mm	1508325-08	1508325-12	1508325-15	1508325-18	1508325-23	1508325-28	1508325-33	1508325-38	3.75 mm
3.5 mm	1508350-08	1508350-12	1508350-15	1508350-18	1508350-23	1508350-28	1508350-33	1508350-38	5.5 mm
4.0 mm	1508400-08	1508400-12	1508400-15	1508400-18	1508400-23	1508400-28	1508400-33	1508400-38	5.5 mm

STENT SPECIFICATIONS		DELIVERY SYSTEM SPECIFICATIONS	
Stent Design	MULTI-LINK, 3-3-3, Peak-to-Valley Design	Nominal Pressure	9 atm for 2.25-2.5 mm; 12 atm for 2.75-4.0 mm
Stent Material	L-605 Cobalt Chromium	Rated Burst Pressure	16 atm for All Diameters
Drug	Everolimus	Shaft Measurements	Proximal 2.1F/0.71 mm Distal 2.7F/0.89 mm
Drug Dose	1 µg/mm²	Min. GC/Sheath Diameter	5F/0.056"/1.42 mm
Polymer	Fluorinated Copolymer	Balloon Material	Pebax <sup>†</sup> 72D
Strut Thickness	0.0032" (81 µm)	Crossing Profile	0.039" (3.0 x 18 mm)
MRI Compatibility	MR Conditional (see IFU for specific conditions)	Tip Entry Profile	0.017" (3.0 x 18 mm)
Shortening	0% (maximum expansion) <sup>1</sup>	Working Catheter Length	145 cm
Post-Dilatation Limit	Sizes 2.25-3.25 mm 3.5-4.0 mm Post-Dil Limit 3.75 mm 5.5 mm		

1. Test(s) performed by and data on file at Abbott

CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at [www.vascular.eifu.abbott](http://www.vascular.eifu.abbott) or at [medical.abbott/manuals](http://medical.abbott/manuals) for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.


Information contained herein for DISTRIBUTION outside the U.S. only. Check the regulatory status of the device in areas where CE marking is not the regulation in force.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.

Abbott International BVBA  
Park Lane, Culliganlaan 2B, 1831 Diegem, Belgium, Tel: 32.2.714.14.11

™ Indicates a trademark of the Abbott Group of Companies.  
† Indicates a third-party trademark, which is property of its respective owner.

[www.cardiovascular.abbott](http://www.cardiovascular.abbott)  
©2020 Abbott. All rights reserved. MAT-2010444 v1.0



Redefining deliverability in complex lesions



1. 15,000,000 implants number is based on data of DES implants through Q1 2020. Data on file at Abbott.

2. Généreux P, et al. *Circ Cardiovasc Interv.* 2015;8(5):1-16; Natsuaki et al., *Cardiovasc Interv and Ther.* 2016. 31:196–209; Watanabe H, et al. *JAMA.* 2019;321(24):2414-2427; Hahn J, et al. ACC 2019 – SMART CHOICE; Valgimigli M, et al. *Circulation.* 2012;125:2015-2026; Gilard M, et al. *J Am Coll Cardiol* 2015;65:777-786; Hong SJ, et al. *J Am Coll Cardiol Intv.* 2016;9:1438–1446. Gwon HC, et al. ACC 2011 - EXCELLENT.

3. Watanabe H, et al. *JAMA.* 2019;321(24):2414-2427 - STOPDAPT 2.



# Redefining deliverability in complex lesions

## XIENCE PRO™ S STENT DESIGN

→ PRECISE

- 100% accurate marker placement<sup>1</sup>
- Zero shortening for precise stent placement<sup>2</sup>

→ STRONG

- Great longitudinal strength<sup>1</sup>
- Outstanding stent retention<sup>1</sup>
- Robust radial strength<sup>1</sup>

→ SLIM

- Ultra low crossing profile<sup>3</sup>

SLIM FLEX TECHNOLOGY

Includes tight crests and smooth links that allow tighter crimping for low crossing profile<sup>1</sup>

ELONGATED BAR ARMS

Deliver up to 5.5 mm maximum expansion in 3.5 mm and 4.0 mm diameter sizes<sup>1</sup>


STENT DELIVERY SYSTEM FOR COMPLEX CASES

Design innovations built to provide the flexibility, crossability, and pushability needed for even the most complex cases

## ULTRA LOW CROSSING PROFILE<sup>3</sup>



1. Data on file at Abbott.  
2. Test(s) performed by and data on file at Abbott. Refers to 4.0 mm diameter size expanded to 5.5 mm.  
3. Test(s) performed by and data on file at Abbott. 3.0 mm diameter size tested, compared to XIENCE Pro A, Synergy, Resolute Onyx.



1. Test(s) performed by and data on file at Abbott.

## SPECIFICALLY DESIGNED FOR THE TREATMENT OF EVEN COMPLEX PATIENTS

LARGE VESSELS

- Post-dilatation up to 5.5 mm<sup>1</sup>
- Superior coating<sup>2</sup> integrity, even at max expansion<sup>3</sup>
- Zero shortening<sup>3</sup>

SIDE BRANCH ACCESS

- Largest side branch access in workhorse sizes<sup>2</sup>
- Stent design maintains integrity even when cell is opened<sup>4</sup>

RADIAL ACCESS

- Unsurpassed pushability: Requires less force to cross lesion<sup>4</sup>
- 5 French compatible
- Ultra low crossing profile<sup>4</sup>

CTO

- True Center Tip designed succeed in CTOs
- Ultra low crossing profile<sup>4</sup>
- The only CTO-indicated stent
- Unrivald safety in CTOs<sup>5</sup>

DIABETES

- Long lengths for small vessels
- Less force needed to cross tight lesions<sup>4</sup>
- Proven safety and efficacy in diabetic patients<sup>6</sup>

1. Test(s) performed by and data on file at Abbott. 5.5 mm maximum expansion in 3.5 and 4.0 diameter sizes.  
2. Test(s) performed by and data on file at Abbott.  
3. Test(s) performed by and data on file at Abbott. Refers to 4.0 mm diameter size expanded to 5.5 mm.  
4. Test(s) performed by and data on file at Abbott. 3.0 mm diameter size tested, compared to XIENCE Pro A, Synergy, Resolute Onyx.  
5. EXPERT CTO Trial data demonstrated 1% definite stent thrombosis and 6.3% TLR at 1 year. Kandzari D, et al. "Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary Occlusion Revascularization." JACC 2015.  
6. TUXEDO 2-Year Data, Upendra Kaul, TCT 2016.